Recombinant Anti-BRAF (phospho S729) antibody [EPR2207] (ab124794)


  • Product name

    Anti-BRAF (phospho S729) antibody [EPR2207]
    See all BRAF primary antibodies
  • Description

    Rabbit monoclonal [EPR2207] to BRAF (phospho S729)
  • Host species

  • Specificity

    Detects B Raf only when phosphorylated on serine 729.
  • Tested applications

    Suitable for: WB, IHC-Pmore details
    Unsuitable for: Flow Cyt,ICC/IF or IP
  • Species reactivity

    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide corresponding to Human BRAF.

  • Positive control

    • PC-12 cell lysates
  • General notes



    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.



Our Abpromise guarantee covers the use of ab124794 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Predicted molecular weight: 84 kDa.
IHC-P 1/100 - 1/250. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
  • Application notes
    Is unsuitable for Flow Cyt,ICC/IF or IP.
  • Target

    • Function

      Involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron.
    • Tissue specificity

      Brain and testis.
    • Involvement in disease

      Note=Defects in BRAF are found in a wide range of cancers.
      Defects in BRAF may be a cause of colorectal cancer (CRC) [MIM:114500].
      Defects in BRAF are involved in lung cancer (LNCR) [MIM:211980].
      Defects in BRAF are involved in non-Hodgkin lymphoma (NHL) [MIM:605027]. NHL is a cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss.
      Defects in BRAF are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.
      Defects in BRAF are the cause of Noonan syndrome type 7 (NS7) [MIM:613706]. Noonan syndrome is a disorder characterized by facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears. Other features can include short stature, a short neck with webbing or redundancy of skin, cardiac anomalies, deafness, motor delay and variable intellectual deficits.
      Defects in BRAF are the cause of LEOPARD syndrome type 3 (LEOPARD3) [MIM:613707]. LEOPARD3 is a disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness.
      Note=A chromosomal aberration involving BRAF is found in pilocytic astrocytomas. A tandem duplication of 2 Mb at 7q34 leads to the expression of a KIAA1549-BRAF fusion protein with a constitutive kinase activity and inducing cell transformation.
    • Sequence similarities

      Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. RAF subfamily.
      Contains 1 phorbol-ester/DAG-type zinc finger.
      Contains 1 protein kinase domain.
      Contains 1 RBD (Ras-binding) domain.
    • Cellular localization

      Nucleus. Cytoplasm. Cell membrane. Colocalizes with RGS14 and RAF1 in both the cytoplasm and membranes.
    • Information by UniProt
    • Database links

    • Alternative names

      • FLJ95109 antibody
      • 94 kDa B raf protein antibody
      • B raf 1 antibody
      • B raf antibody
      • B Raf proto oncogene serine threonine protein kinase antibody
      • B Raf proto oncogene, serine/threonine kinase antibody
      • B RAF1 antibody
      • B-Raf proto-oncogene serine/threonine-protein kinase (p94) antibody
      • BRAF 1 antibody
      • BRAF antibody
      • BRAF_HUMAN antibody
      • BRAF1 antibody
      • cRmil antibody
      • MGC126806 antibody
      • MGC138284 antibody
      • Murine sarcoma viral (v-raf) oncogene homolog B1 antibody
      • Murine sarcoma viral v raf oncogene homolog B1 antibody
      • NS7 antibody
      • Oncogen BRAF antibody
      • oncogene BRAF1 antibody
      • p94 antibody
      • Proto-oncogene B-Raf antibody
      • Proto-oncogene c-Rmil antibody
      • RAFB 1 antibody
      • RAFB1 antibody
      • RMIL antibody
      • Serine/threonine-protein kinase B-raf antibody
      • v raf murine sarcoma viral oncogene homolog B antibody
      • v raf murine sarcoma viral oncogene homolog B1 antibody
      • v-Raf murine sarcoma viral oncogene homolog B1 antibody
      see all


    • All lanes : Anti-BRAF (phospho S729) antibody [EPR2207] (ab124794) at 1/1000 dilution

      Lane 1 : PC-12 cell lysates (untreated)
      Lane 2 : PC-12 cell lysates treated with Lambda Phosphatase

      Lysates/proteins at 10 µg per lane.

      All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution

      Predicted band size: 84 kDa

    • Equilibrium disassociation constant (KD)
      Learn more about KD

      Click here to learn more about KD


    This product has been referenced in:

    • Zhang Y  et al. Glycyrrhetinic acid binds to the conserved P-loop region and interferes with the interaction of RAS-effector proteins. Acta Pharm Sin B 9:294-303 (2019). Read more (PubMed: 30976491) »
    • Vido MJ  et al. BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association. Cell Rep 25:1501-1510.e3 (2018). Read more (PubMed: 30404005) »
    See all 3 Publications for this product

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab124794.
    Please use the links above to contact us or submit feedback about this product.

    For licensing inquiries, please contact

    Sign up